Cancer diagnostics with ctDNA
Unlocking the Future of Cancer Diagnostics with Circulating Tumor DNA (ctDNA) Advances in cancer research have brought us...
About Us
- Home
- About Us
Who we are
Liquid biopsy is revolutionizing tumor diagnostics. LIQOMICS is an academic spin-off company from Cologne, Germany. We aspire to bring our cutting-edge liquid biopsy technology for genotyping and disease monitoring to patients worldwide.
Some key statistics of our assay
- Sensitivity for Genotyping (SNPs / InDels) > 93%
- Specificity for Genotyping (SNPs / InDels) > 99.999%
- Sensitivity for MRD detection at MRD level of > 10-5 > 88%
- Specificity for MRD detection at MRD level of > 10-5 > 99%
- Limit of Detection for MRD ~5 x 10-6
Awards
Certifications & Standards
We work in conformity with the RiliBÄK guidelines of the German Medical Association
Certification Process Ongoing
In clinical trials we work in conformity with ICH-GCP (Good Clinical Practice)
You will be able to find our team here soon!
Our Team
How We Work
Partner with us
We are always on the lookout for collaborators.
Academic research, start-up or pharmaceutical industry. If you are excited about blood-based cancer genomics or highly sensitive minimal residual disease assessment across cancers we should start a conversation.
Get in contact with us and let us explore how we can team up.
Lates News & Articles
Minimal residual disease (MRD) in liquid biopsy
Minimal Residual Disease (MRD) in liquid biopsy (Part II) In our previous article, we explored the importance of...
Minimal Residual Disease (MRD) in cancer
Minimal Residual Disease (MRD) in cancer (Part I) Introduction In the field of cancer treatment, early and accurate...